Concern Over Fast Tracking of New Drugs (press release)

Breaking News for Tuesday, December 02, 2008 Government Task Force Predicts Terror Attack on Major U.S. City by 2013 PepsiCo Ready to Launch Stevia Sweetened Diet Sodas Melamine Found Contaminating Soy Meal Fed to Organic Chickens Health Ranger to be Guest on Alex Jones Show, Tuesday at 2PM Central Time Doctors Abandoning Vaccines That Don't Make Them Money      See all Breaking News... FREE Natural Health Newsletter Receive natural health product reviews, recommendations and alerts. Instant download of 20+ free health reports and exclusive interviews. Join over 1.2 million monthly readers. Unsubscribe anytime, email privacy guaranteed Products Related to This Article* • Revealed: Natural Health Solutions (free) Free summary of book by Mike Adams for learning censored natural health remedies • Free download: Selling Sickness (summary) Read the best book on disease mongering for learning the truth about Big Pharma * Recommended by the Health Ranger. See more recommendations on right → Articles Related to This Article: • Harvard study finds high vitamin D intake may cut multiple sclerosis risk • Questions Over Accuracy of MRI in Diagnosing Multiple Sclerosis (press release) • STANFORD DOCTORS SPOTLIGHT FATAL FLAW IN MULTIPLE SCLEROSIS DRUG TRIAL (press release)

It follows approval of natalizumab, a new drug for multiple sclerosis, and its recall three months later, after three trial patients developed a life threatening condition while being treated.

Natalizumab was licensed by the US Food and Drug Administration in 2004 for use in relapsing multiple sclerosis on the basis of short term results from two unpublished trials. The FDA granted approval before final trial and cumulative safety data were available. Natalizumab was predicted to be the leading drug for multiple sclerosis, with estimated annual sales in excess of $2bn.

Around 3000 patients took part in the trials and nearly 5000 patients have been treated in the United States since it became commercially available. In the United Kingdom, natalizumab was due for appraisal by the National Institute for Health and Clinical Excellence in 2006.

But on 28 February 2005, natalizumab was recalled after three trial patients developed progressive multifocal leucoencephalopathy (PML), a rapidly progressive neurodegenerative disease. Two of the patients died.

The approval of natalizumab and its recall after three months raises questions about the fast tracking of new drugs by the FDA for commercial licensing, says the author, consultant neurologist Abhijit Chaudhuri. It also highlights the potential risks for patients in trials of new drugs where knowledge of long term efficacy, outcome measures, and safety is lacking.

Short term solutions for a chronic disease like multiple sclerosis are not likely to be effective, and experience with natalizumab should be taken as a signal to change the way we treat this disease, he concludes.
Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Harvard study finds high vitamin D intake may cut multiple sclerosis risk • Questions Over Accuracy of MRI in Diagnosing Multiple Sclerosis (press release) • STANFORD DOCTORS SPOTLIGHT FATAL FLAW IN MULTIPLE SCLEROSIS DRUG TRIAL (press release)	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/020059.html Reprinting this article: Non-commercial OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/020059.html">Concern Over Fast Tracking of New Drugs (press release)</a>